CommercialSurrounded by controversy, FDA approves Biogen's Alzheimer's drug Aduhelm

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

-

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm, the very first Alzheimer’s medication in the last two decades, which is manufactured by Biogen Pharma.

“Aduhelm is an antibody that attacks the amyloid plaque that has been found to accumulate in the brains of people who have Alzheimer’s disease,” said Dr. Jeffrey Singer to The National Desk’s Jan Jeffcoat. “The only problem is that there’s still a lot of controversy among researchers as to whether or not those plaques are responsible for dementia or are a byproduct of some sort of another inflammatory process that’s causing dementia.”

The three executives of the expert committee of FDA have resigned in protest of Aduhelm’s approval. Dr. Singer said that the FDA has an expedited system for approval of drugs which makes these medications easily accessible by patients who may not have any time to wait.

Dr. singer claims that before 1962, FDA was only obliged to verify a drug’s safety and accurate labeling, not its efficacy.

Life Sciences Voice Logo mobile
+ posts

Latest news

Top 10 Data Architecture Challenges in Modern Pharma Organizations

Executive Summary Data has become one of the most valuable strategic assets in the pharmaceutical industry. Every stage of the...

The Next Evolution of Decentralized Clinical Trials

Executive Summary Decentralized clinical trials (DCTs) emerged as one of the most significant innovations in clinical research over the past...

Despite a mid-stage miss, Mirum and Incyte strengthen the case for approval in uncommon bone disease

Incyte and Mirum Pharmaceuticals are taking a step closer to approval of their investigational pill for fibrodysplasia ossificans progressiva...

Must read

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC

You might also likeRELATED
Recommended to you